Abstracts tagged "methotrexate (MTX)"

Abstract Number: 615 • 2017 ACR/ARHP Annual Meeting
Efficacy of Tofacitinib By Background Methotrexate Dose in Patients with Psoriatic Arthritis: A Post Hoc Analysis of Pooled Data from 2 Phase 3 Trials
Alan J. Kivitz¹, Oliver FitzGerald², Peter Nash³, Shirley Pang⁴, Valderilio F Azevedo⁵, Elizabeth Kudlacz⁶, Cunshan Wang⁶, Daniela Graham⁶ and Liza Takiya⁷, ¹Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, ²Department of Rheumatology, St Vincent's University Hospital, Dublin, Ireland, ³Department of Medicine, University of Queensland, St Lucia, Brisbane, Australia, ⁴St. Jude Medical Center, Fullerton, CA, ⁵Universidade Federal do Paraná, Curitiba, Brazil, ⁶Pfizer Inc, Groton, CT, ⁷Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor under investigation for psoriatic arthritis (PsA). The efficacy of tofacitinib has been evaluated in 2 Phase 3…
Abstract Number: 2465 • 2017 ACR/ARHP Annual Meeting
Association between Methotrexate Use and Effects of Treatment with a Second Biologic Agent in Rheumatoid Arthritis: A Multiple Imputation Approach
Yoshikazu Ogawa¹, Nobunori Takahashi², Naoki Ishiguro² and Toshihisa Kojima², ¹Sakashita Hospital, Nakatsugawa, Japan, ²Orthopaedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
Background/Purpose: Methotrexate (MTX) is recommended and widely prescribed as the first-line, evidence-based therapy for rheumatoid arthritis (RA) patients. Previous studies have demonstrated a significant effect…
Abstract Number: 804 • 2017 ACR/ARHP Annual Meeting
The Efficacy and Safety of the Anti-IL-6 Receptor Antibody Tocilizumab for Polymyalgia Rheumatica Patients with Resistance or Intolerance to Glucocorticoids and Methotrexate
Manami Hirata¹, Akiko Ueno², kazuyuki fujita², Nobuyuki Shibutou² and Masahiro Yamamura³, ¹Center for Rheumatology, Okayama Saiseikai General Hospital, Okayama, Japan, ²Centor for Rheumatology, Okayama Saiseikai General Hospital, Okayama, Japan, ³Okayama Saiseikai General Hospital, Okayama, Japan
Background/Purpose: Some patients show inadequate responses to initial glucocorticoids (GC) doses or relapses during GC tapering and develop side effects of GCs. The 2015 EULAR/ACR…
Abstract Number: 2962 • 2017 ACR/ARHP Annual Meeting
MRI Results Following Discontinuation of Methotrexate in Patients with Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab: Results from a Randomized Controlled Trial
Charles Peterfy¹, Joel Kremer², William F C Rigby³, Nora Singer⁴, Christine Birchwood⁵, Darcy Gill⁵, William Reiss⁵, Jinglan Pei⁵ and Margaret Michalska⁵, ¹Spire Sciences, Inc., Boca Raton, FL, ²Albany Medical College, Albany, NY, ³Geisel School of Medicine at Dartmouth, Lebanon, NH, ⁴Case Western Reserve University School of Medicine, Cleveland, OH, ⁵Genentech, Inc., South San Francisco, CA
Background/Purpose: Although previous studies have established the efficacy of tocilizumab (TCZ) initiated as monotherapy (MONO) for the treatment of rheumatoid arthritis (RA),1,2 changes in active…
Abstract Number: 827 • 2017 ACR/ARHP Annual Meeting
Temporary Methotrexate Discontinuation for 2 Weeks Improves Immunogenicity of Seasonal Influenza Vaccination in Patients with Rheumatoid Arthritis: A Randomized Clinical Trial
Jin Kyun Park¹, Kichul Shin², You-Jung Ha³, Yun Jong Lee⁴, Eun Young Lee⁵, Yeong Wook Song⁶, Yunhee Choi⁷, Kevin Winthrop⁸ and Eun Bong Lee⁹, ¹Division of Rheumatology, Seoul National University Hospital, Seoul, Korea, Republic of (South), ²Kyungnam villa #102, Division of Rheumatology, Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of (South), ³Yonsei University College of Medicine, Seoul, Korea, Republic of (South), ⁴Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea, Republic of (South), ⁵Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, Korea, Republic of (South), ⁶Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine, Seoul National University, Seoul, Korea, The Republic of, Seoul, Korea, Republic of (South), ⁷Division of Medical Statistics, Medical Research Collaborating Center, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), ⁸Oregon Health & Science University, Portland, OR, ⁹Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of (South)
Background/Purpose: Methotrexate (MTX), a widely used immune-suppressive agent, decreases vaccine response in patients with rheumatoid arthritis (RA). We investigated whether a temporary MTX discontinuation for…
Abstract Number: 1252 • 2017 ACR/ARHP Annual Meeting
Real-World Oral Methotrexate Adherence Measured Electronically in Patients with Established Rheumatoid Arthritis
Kaleb Michaud^1,2, Rebecca Schumacher², Bernard Vrijens³, Eric Tousset³, Gorana Dasic⁴, Connie Chen⁴, Ekta Agarwal⁴ and Maria Suarez-Almazor⁵, ¹University of Nebraska Medical Center, Omaha, NE, ²National Data Bank for Rheumatic Diseases, Wichita, KS, ³WestRock Healthcare, Visé, Belgium, ⁴Pfizer Inc, New York, NY, ⁵Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX
Background/Purpose: While weekly methotrexate (MTX) remains the gold standard treatment for patients with RA, studies suggest that MTX adherence may be sub-optimal and could be…
Abstract Number: 1322 • 2017 ACR/ARHP Annual Meeting
Tissue Folate Dysregulation Is Associated with Disease Activity and Methotrexate Response in Collagen-Induced Arthritis
Leon van Haandel¹, Rakesh Singh², Paul Kiptoo³, Teruna Siahaan³, Mara L Becker⁴ and Ryan Funk⁵, ¹2401 Gillham Road, Children's Mercy, Kansas City, MO, ²Department of Pharmacy Practice, University of Kansas Medical Center, Kansas City, KS, ³Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS, ⁴Rheumatology, Children's Mercy Kansas City, Kansas City, MO, ⁵University of Kansas Medical Center, Kansas City, KS
Background/Purpose: Methotrexate (MTX) is an anti-metabolite inhibitor of folate-dependent biochemical pathways and is effective in reducing disease activity in autoimmune arthritis. This work seeks to…
Abstract Number: 1399 • 2017 ACR/ARHP Annual Meeting
Tissues Are Differently Modulated By Tocilizumab and Methotrexate; Assessment of Connective Tissue Metabolites in the Ambition Study
Anne C. Bay-Jensen¹, Anne Sofie Siebuhr¹, Christian S. Thudium² and Morten Asser Karsdal¹, ¹Rheumatology, Nordic Bioscience, Herlev, Denmark, ²Biomarkers and Research, Nordic Bioscience, Herlev, Denmark
Background/Purpose: The response to any treatment in rheumatoid arthritis (RA) is assessed by symptomatic changes, such as swollen joint count and DAS28. However, such assessments…
Abstract Number: 1430 • 2017 ACR/ARHP Annual Meeting
Switching from Synthetic to Biologic Dmards – Is There an Insufficient Use of Methotrexate?
Lisa Baganz¹, Adrian Richter¹, Yvette Meißner², Matthias Schneider³, Anke Liebhaber⁴, Ilka Schwarze⁵, Anja Strangfeld⁶ and Angela Zink⁷, ¹German Rheumatism Research Center, Berlin, Germany, ²Programme Area Epidemiology, German Rheumatism Research Center, Berlin, Germany, ³Department of Rheumatology, Univ. Duesseldorf, Duesseldorf, Germany, ⁴Rheumatologist, Halle, Germany, Halle, Germany, ⁵Rheumatologist, Leipzig, Germany, Leipzig, Germany, ⁶Epidemiology, German Rheumatism Research Center, Berlin, Germany, ⁷German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany
Background/Purpose: A recent US-study suggests considerable underuse of MTX and too early switches to biologic (b)DMARDs1 before using a high MTX dose or changing the…
Abstract Number: 1476 • 2017 ACR/ARHP Annual Meeting
Effect of Treat-to-Target Tocilizumab- and Methotrexate-Based Strategies on Health-Related Quality of Life in Newly Diagnosed Rheumatoid Arthritis Patients: Results of the U-Act-Early Trial
Xavier M Teitsma¹, Johannes WG Jacobs¹, Paco MJ Welsing², Attila Pethö-Schramm³, Michelle EA Borm⁴, Jacob M. van Laar⁵, Floris PJ Lafeber⁵ and Johannes W.J. Bijlsma², ¹Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³F. Hoffmann-La Roche, Basel, Switzerland, ⁴Beneluxlaan 2a, Roche Nederland BV, Woerden, Netherlands, ⁵Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Patient-reported outcomes are, in addition to other efficacy and safety related outcomes, important reflections of effectiveness and adverse effects of a therapy. The Outcomes…
Abstract Number: 1815 • 2017 ACR/ARHP Annual Meeting
Patterns of Methotrexate Use and Discontinuation in a U.S. Rheumatoid Arthritis Registry
Jeffrey R. Curtis¹, Gene Wallenstein², Liza Takiya³, David Gruben², Connie Chen⁴, Ying Shan⁵, Taylor Blachley⁵, Kimberly J Dandreo⁵ and Joel Kremer⁶, ¹University of Alabama at Birmingham, Birmingham, AL, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Collegeville, PA, ⁴Pfizer Inc, New York, NY, ⁵Corrona, LLC, Southborough, MA, ⁶Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: Methotrexate (MTX) remains a cornerstone therapy in the management of rheumatoid arthritis (RA), but patterns of adherence, intolerance, and inadequate response are not well…
Abstract Number: 1905 • 2017 ACR/ARHP Annual Meeting
Sustained Response Following Discontinuation of Methotrexate in Patients with Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab: Results from a Randomized Controlled Trial
Joel Kremer¹, William F C Rigby², Nora Singer³, Christine Birchwood⁴, Darcy Gill⁴, William Reiss⁴, Jinglan Pei⁴ and Margaret Michalska⁴, ¹Albany Medical College, Albany, NY, ²Geisel School of Medicine at Dartmouth, Lebanon, NH, ³Case Western Reserve University School of Medicine, Cleveland, OH, ⁴Genentech, Inc., South San Francisco, CA
Background/Purpose: Although methotrexate (MTX) is often administered in combination with biologics for the treatment of rheumatoid arthritis (RA), it may be discontinued due to intolerance…
Abstract Number: 49 • 2017 Pediatric Rheumatology Symposium
Perceptions of Methotrexate Intolerance in School-aged Children With Juvenile Idiopathic Arthritis
Charlene Hopper¹, Sarah Khan², Jacqueline Mancini² and Janet Rennick^3,4, ¹Rheumatology, Montreal Children's Hospital McGill University Health Centre, Montreal, QC, Canada, ²Ingram School of Nursing, McGill University, Montreal, QC, Canada, ³Nursing, Montreal Children's Hospital McGill University Health Centre, Montreal, QC, Canada, ⁴Ingram School of Nursing and Department of Pediatrics, McGill University, Montreal, QC, Canada
Background/Purpose: Methotrexate (MTX) remains an effective and commonly used disease modifying anti-rheumatic drug (DMARD) for the treatment of Juvenile Idiopathic Arthritis (JIA). Approximately half of the children taking MTX will…
Abstract Number: 1302 • 2016 ACR/ARHP Annual Meeting
Silent Progression in Patients with Rheumatoid Arthritis: Is DAS28 Remission an Insufficient Goal in RA? Results from the German Remission-PLUS Cohort
Dr. Philipp Sewerin¹, PD Dr. Stefan Vordenbäumen¹, Annika Hoyer², Ralph Brinks¹, Dr. Christian Buchbender³, Dr. Christoph Schleich⁴, Sabine Kamp¹, Prof. Dr. Gerald Antoch³, Prof. Dr. Matthias Schneider¹ and Prof. Dr. Benedikt Ostendorf¹, ¹Department of Rheumatology & Hiller Research Unit, Heinrich-Heine University, Düsseldorf, Germany, ²Institute for Biometry and Epidemiology, German Diabetes Center, Duesseldorf, Germany, ³Diagnostic and Interventional Radiology, Heinrich-Heine-University, Düsseldorf, Germany, ⁴Dep. for diagnostic and interventional Radiology, Heinrich-Heine-University, Duesseldorf, Germany
Background/Purpose: disease activity score in 28 joints; Methods: Data-sets of 80 RA patients from the REMISSION-plus study cohort who fulfilled the following criteria were retrospectively…
Abstract Number: 1596 • 2016 ACR/ARHP Annual Meeting
Comparative Effectiveness of Tocilizumab Monotherapy with Tumor Necrosis Factor Inhibitors in Combination with Methotrexate in Patients with Rheumatoid Arthritis and Prior Exposure to Tumor Necrosis Factor Inhibitors
Leslie R. Harrold^1,2, George W. Reed^1,2, Jennie Best³, Steve Zlotnick³, Gioia Persuitte² and Joel M. Kremer⁴, ¹University of Massachusetts Medical School, Worcester, MA, ²Corrona, LLC, Southborough, MA, ³Genentech, Inc., South San Francisco, CA, ⁴The Albany Medical College, Albany, NY
Background/Purpose: Clinical studies have demonstrated the superior efficacy of tocilizumab monotherapy (TCZ mono) to tumor necrosis factor inhibitor (TNFi) monotherapy and the comparable efficacy of…

« Previous Page
1
…
4
5
6
7
8
…
16
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.